Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24419340)

1.

Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, Vela JE, Shih R, Birkus G, Stefanidis D, Kim CU, Cho A, Ray AS.

Antimicrob Agents Chemother. 2014;58(4):1943-51. doi: 10.1128/AAC.02350-13. Epub 2014 Jan 13.

2.

Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.

Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS.

Mol Pharm. 2013 Feb 4;10(2):459-66. doi: 10.1021/mp3002045. Epub 2012 Jul 12.

PMID:
22738467
3.

Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Gupta D, Varghese Gupta S, Dahan A, Tsume Y, Hilfinger J, Lee KD, Amidon GL.

Mol Pharm. 2013 Feb 4;10(2):512-22. doi: 10.1021/mp300564v. Epub 2013 Jan 4.

4.
5.

Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.

Prueksaritanont T, Gorham LM, Ellis JD, Fernandez-Metzler C, Deluna P, Gehret JR, Strong KL, Hochman JH, Askew BC, Duggan ME, Gilbert JD, Lin JH, Vyas KP.

Drug Metab Dispos. 1996 Nov;24(11):1263-71.

PMID:
8937862
6.

Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.

Yan Z, Sun J, Chang Y, Liu Y, Fu Q, Xu Y, Sun Y, Pu X, Zhang Y, Jing Y, Yin S, Zhu M, Wang Y, He Z.

Mol Pharm. 2011 Apr 4;8(2):319-29. doi: 10.1021/mp100376q. Epub 2011 Mar 4.

PMID:
21280612
8.

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters CR, Wang J, Williams K, Patti JM, Henson G, Madela K, Aljarah M, Gilles A, McGuigan C.

Antimicrob Agents Chemother. 2011 May;55(5):1843-51. doi: 10.1128/AAC.01335-10. Epub 2011 Feb 28.

10.

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26.

PMID:
19396600
11.

Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.

Cook CS, Karabatsos PJ, Schoenhard GL, Karim A.

Pharm Res. 1995 Aug;12(8):1158-64.

PMID:
7494828
12.

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA.

J Med Chem. 2010 Oct 14;53(19):7202-18. doi: 10.1021/jm100863x.

PMID:
20845908
13.

Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, Cundy KC.

Pharm Res. 1997 Dec;14(12):1824-9.

PMID:
9453075
14.

Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB.

Antimicrob Agents Chemother. 1998 Mar;42(3):647-53.

15.
16.

Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Bobeck DR, Schinazi RF, Coats SJ.

Antivir Ther. 2010;15(7):935-50. doi: 10.3851/IMP1667. Review.

PMID:
21041908
17.

Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.

Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL.

J Pharmacol Exp Ther. 2005 Aug;314(2):883-90. Epub 2005 May 18.

18.

Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.

Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, Eng S, Tirunagari N, Peng B, Yu M, Tian Y, Lee YJ, Stepan G, Lagpacan LL, Jin D, Hung M, Ku KS, Han B, Kitrinos K, Perron M, Birkus G, Wong KA, Zhong W, Kim CU, Carey A, Cho A, Ray AS.

Antimicrob Agents Chemother. 2014;58(4):1930-42. doi: 10.1128/AAC.02351-13. Epub 2014 Jan 13.

19.

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Kamath AV, Wang J, Lee FY, Marathe PH.

Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.

PMID:
17429625
20.

Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs.

Oliyai R, Arimilli MN, Jones RJ, Lee WA.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1411-4.

PMID:
11563033
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk